AtomVie Global Radiopharma and TerraPower Isotopes have entered into a supply agreement for Actinium-225, a key isotope for radiopharmaceuticals. This collaboration aims to enhance the supply chain and expedite the development of targeted therapies for cancer and other diseases. The agreement supports both early and late-stage development programs and improves developmental flexibility. AtomVie CEO Bruno Paquin highlighted the importance of this partnership in advancing innovative therapies worldwide, while TerraPower Isotopes President Scott Claunch emphasized the role of their high-purity Ac-225 in enhancing treatment options for patients. Both organizations are committed to advancing nuclear medicine and expanding access to cutting-edge therapies.
Tue, 17 Jun 2025 13:00:00 GMT | PR Newswire